Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine

Human Vaccines

Volumn 5, Issue 9, 2009, Pages 592-598

  Zinke, Michael ^a   Kappes, Rudolf ^b   Kindler, Klaus ^c   Paulus Koschik, Anke ^d   Goering, Uwe ^e   Disselhoff, Johann ^f   Soemantri, Peter ^f   Grunert, Detlef ^g   Laakmann, Karl Heinz ^d   Gunasekaran, Ramakrishnan ^h,i,j   Gartner, Britta ^h,i,j   Jacquet, Jeanne Marie ^h,i,j  

^a Gemeinschaftspraxis ^*  (Germany)

^b Gemeinschaftspraxis   (Germany)

^c Praxisgemeinschaft Dres   (Germany)

^d Arztpraxis Nördlingen ^*

^e GlaxoSmithKline Biologicals ^*  (Germany)

^f Medical Practice   (Germany)

^g Arztpraxis Nördlingen   (Germany)

^h GlaxoSmithKline Pharmaceuticals Ltd   (India)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

more..

Author keywords

Booster; DTPa HBV IPV Hib; Hepatitis B; Hexavalent; Seroprotection; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECHALLENGE; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; SINGLE DRUG DOSE;

EID: 73649127574     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.9051     Document Type: Article

References (29)

1. World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull WHO 1988; 66:443-55.
2. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5:79-84.
3. Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-66.
4. Bialek S, Bower W, Novak R, Helgenberger L, Auerbach S, Williams I, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-5.
5. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64.
6. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:373-81.
7. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-26.
8. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25:8085-90.
9. Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 2007; 25:7160-7.
10. Zanetti AR, Mariano A, Romanò L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84.
11. Da Villa G, Romano L, Sepe A, Iorio R, Paribello N, Zappa A, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25:3133-6.
12. World Health Organization. Core information for the development of immunization policy. Document WHO/V&B/02.28, 2002. Geneva, WHO 2002.
13. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5.
14. La Torre G, Nicolotti N, de Waure C, Chiaradia G, Specchia ML, Mannocci A, et al. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. Virol J 2008; 5:84.
15. Mele A, Tosti ME, Mariano A, Pizzuti R, Ferro A, Borrini B, et al. Acute Hepatitis B 14 Years after the Implementation of Universal Vaccination in Italy: Areas of Improvement and Emerging Challenges. Clin Infect Dis 2008; 46:868-75.
16. But DY-K, Lai C-L, Limb W-L, Funga J, Wonga DK-H, Yuena M-F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children. Vaccine 2008; e-published doi:10.1016/j. vaccine.2008.09.034.
17. AlFaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 2008;57:404-9.
18. Zanetti A, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008; 26:6266-73.
19. Lim FS, Han HH, Jacquet JM, Bock HL. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore 2007; 36:801-6.
20. Curran MP, Goa KL. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). Drugs 2003; 63:673-82.
21. Heininger U; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055-63.
22. Duval B, Gîlca V, Boulianne N, De Wals P, Massé R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005;24:213-8.
23. Raz R, Dagan R, Gallil A, Brill G, Kassis I, Koren R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 1996; 14:207-11.
24. Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23:3272-9.
25. Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Human Vaccine 2006; 2:249-54.
26. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2005; 24:70-7.
27. Saenger R, Maechler G, Potreck M, Zepp F, Knuf M, Habermehl P, et al. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 2005; 23:1135-43.
28. Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004; 22:2226-33.
29. th ESPID meeting, Graz, Austria 2008.